Running Interference: RNAi With Silence Therapeutics' Craig Tooman
Source: Bioprocess Online
Fresh on the heels of his appointment as President & CEO at Silence Therapeutics, Craig Tooman joins the Business of Biotech to share how he applies his finance-minded leadership to steward the advance of the company's deepening pipeline of RNAi gene silencing candidates. Tooman also shares insight into the IP and the people responsible for managing that deep pipeline, which spans indications from hematology to cardiovascular disease to rare diseases.
This website uses cookies to ensure you get the best experience on our website. Learn more